Fig. 3
From: Effects of antivirals on patients with COVID-19 breakthrough
Effects of antivirals among subgroups on the risks of residual respiratory symptoms (primary outcome) and long COVID-19 (secondary outcome)
Abbreviation: CI: confidence interval; NA: not available/not applicable; SoC: standard of care
Note: NAs were due to no or too few events being observed. Reference levels of the primary and secondary outcomes were symptom-free status within ≤ 7 days and no signs/symptoms of long COVID-19, respectively. Panel A: primary outcome. Panel B: secondary outcome